InnoCan Pharma Corporation (CSE:INNO)

Market Cap	64.33M
Revenue (ttm)	43.79M
Net Income (ttm)	-932.84K
Shares Out	292.42M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	321,700
Average Volume	42,954
Open	0.2100
Previous Close	0.2250
Day's Range	0.2100 - 0.2300
52-Week Range	0.1500 - 0.3000
Beta	-0.29
RSI	67.00
Earnings Date	Aug 12, 2025

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for e...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: INNO

Financial Performance

In 2024, InnoCan Pharma's revenue was $29.44 million, an increase of 115.55% compared to the previous year's $13.66 million. Losses were -$1.83 million, -60.98% less than in 2023.

Financial numbers in USD